Peddock Capital Advisors LLC Sells 11,222 Shares of CVS Health Co. (NYSE:CVS)

Peddock Capital Advisors LLC lessened its stake in CVS Health Co. (NYSE:CVS) by 64.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,085 shares of the pharmacy operator’s stock after selling 11,222 shares during the period. Peddock Capital Advisors LLC’s holdings in CVS Health were worth $273,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Sound Income Strategies LLC increased its stake in shares of CVS Health by 7.2% in the 3rd quarter. Sound Income Strategies LLC now owns 2,397 shares of the pharmacy operator’s stock valued at $151,000 after acquiring an additional 162 shares in the last quarter. Hexagon Capital Partners LLC increased its stake in CVS Health by 3.5% in the third quarter. Hexagon Capital Partners LLC now owns 5,268 shares of the pharmacy operator’s stock valued at $331,000 after purchasing an additional 178 shares in the last quarter. Bruce G. Allen Investments LLC boosted its position in shares of CVS Health by 13.1% during the 3rd quarter. Bruce G. Allen Investments LLC now owns 1,681 shares of the pharmacy operator’s stock worth $106,000 after purchasing an additional 195 shares in the last quarter. Integrated Advisors Network LLC grew its stake in shares of CVS Health by 0.7% in the 3rd quarter. Integrated Advisors Network LLC now owns 27,625 shares of the pharmacy operator’s stock valued at $1,737,000 after buying an additional 200 shares during the period. Finally, Widmann Financial Services Inc. raised its stake in CVS Health by 1.8% during the 3rd quarter. Widmann Financial Services Inc. now owns 11,506 shares of the pharmacy operator’s stock worth $724,000 after buying an additional 200 shares during the period. 80.66% of the stock is currently owned by institutional investors.

CVS Health Price Performance

NYSE:CVS traded up $3.53 during mid-day trading on Monday, hitting $51.54. 25,636,260 shares of the stock traded hands, compared to its average volume of 15,179,041. The business’s 50-day moving average price is $51.82 and its 200 day moving average price is $56.55. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 12-month low of $43.56 and a 12-month high of $80.75. The company has a market cap of $64.86 billion, a PE ratio of 13.08, a price-to-earnings-growth ratio of 0.85 and a beta of 0.59.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.08 by $0.01. The business had revenue of $95.43 billion during the quarter, compared to analysts’ expectations of $92.72 billion. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.21 earnings per share. On average, analysts expect that CVS Health Co. will post 5.32 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd will be given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 5.16%. The ex-dividend date of this dividend is Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is currently 67.51%.

Analyst Upgrades and Downgrades

CVS has been the topic of several recent research reports. Truist Financial dropped their price target on shares of CVS Health from $67.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Barclays reduced their price objective on shares of CVS Health from $75.00 to $71.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. Royal Bank of Canada cut their target price on CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $62.00 price target on shares of CVS Health in a research report on Tuesday, October 1st. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $68.71.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.